冠状病毒的糖衣外壳作为候选疫苗。
Coronaviruses' sugar shields as vaccine candidates.
作者信息
Wang Denong
机构信息
Tumor Glycomics Laboratory, SRI International Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA, USA.
出版信息
Curr Trends Immunol. 2020;21:17-23.
Abstract
A successful global healthcare response relies on versatile vaccines and production of broadly virus-neutralizing antibodies by the immune system to protect us from emerging infectious diseases. The present 2019 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic highlights the urgent need for development of anti-viral biodefense. Due to the genetic and proteomic diversities of viral pathogens, establishing versatile anti-viral vaccines or therapeutic agents is highly challenging. Carbohydrate antigens represent an important class of immunological targets for vaccine development and immunotherapy against microbial infections. In this mini review, some concepts and strategies for exploring the potential of immunogenic sugar moieties as CoV vaccine candidates are presented.
摘要
成功的全球医疗应对依赖于多功能疫苗以及免疫系统产生广泛的病毒中和抗体，以保护我们免受新出现的传染病侵害。当前的2019年严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行凸显了开发抗病毒生物防御的迫切需求。由于病毒病原体的遗传和蛋白质组多样性，建立多功能抗病毒疫苗或治疗剂极具挑战性。碳水化合物抗原是疫苗开发和针对微生物感染的免疫治疗的一类重要免疫靶点。在这篇小型综述中，介绍了一些探索免疫原性糖部分作为冠状病毒疫苗候选物潜力的概念和策略。
相似文献
1
Coronaviruses' sugar shields as vaccine candidates.冠状病毒的糖衣外壳作为候选疫苗。
Curr Trends Immunol. 2020;21:17-23.
2
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).单克隆抗体治疗作为潜在治疗干预手段用于新型冠状病毒病-19（COVID-19）的观点。
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18. doi: 10.12932/AP-200220-0773.
3
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
4
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
5
Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.靶向N-聚糖隐蔽糖基部分以实现广谱病毒中和：在鉴定不同系统发育起源病毒中保守分子靶点方面的进展
Molecules. 2015 Mar 12;20(3):4610-22. doi: 10.3390/molecules20034610.
6
Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus.豇豆花叶病毒纳米颗粒疫苗候选物展示的肽表位可中和严重急性呼吸综合征冠状病毒。
ACS Infect Dis. 2021 Nov 12;7(11):3096-3110. doi: 10.1021/acsinfecdis.1c00410. Epub 2021 Oct 21.
7
Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.基于刺突蛋白的 SARS 亚单位疫苗候选物的保护性免疫：冠状病毒疫苗开发的经验教训。
J Immunol Res. 2020 Jul 18;2020:7201752. doi: 10.1155/2020/7201752. eCollection 2020.
8
Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.利用预先存在的流感病毒特异性免疫力可增强针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应。
J Virol. 2024 Feb 20;98(2):e0157123. doi: 10.1128/jvi.01571-23. Epub 2024 Jan 11.
9
Neutralizing antibodies mediate virus-immune pathology of COVID-19.中和抗体介导 COVID-19 的病毒免疫病理学。
Med Hypotheses. 2020 Oct;143:109884. doi: 10.1016/j.mehy.2020.109884. Epub 2020 May 30.
10
A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.脂质纳米颗粒-mRNA 疫苗鸡尾酒增强了小鼠模型中针对 β-冠状病毒的免疫反应。
Viruses. 2024 Mar 21;16(3):484. doi: 10.3390/v16030484.
引用本文的文献
1
Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields.由 N-聚糖盾牌介导的同时针对 SARS-CoV-2 的中和抗体。
Viruses. 2023 Oct 12;15(10):2079. doi: 10.3390/v15102079.
2
Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking.糖基化和S-棕榈酰化调节严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的细胞内运输。
iScience. 2022 Aug 19;25(8):104709. doi: 10.1016/j.isci.2022.104709. Epub 2022 Jul 3.
3
Customized peptidoglycan surfaces to investigate innate immune recognition via surface plasmon resonance.通过表面等离子体共振技术研究固有免疫识别的定制肽聚糖表面。
Methods Enzymol. 2022;665:73-103. doi: 10.1016/bs.mie.2021.12.004. Epub 2022 Jan 13.
4
The glycosylation in SARS-CoV-2 and its receptor ACE2.SARS-CoV-2 及其受体 ACE2 的糖基化。
Signal Transduct Target Ther. 2021 Nov 15;6(1):396. doi: 10.1038/s41392-021-00809-8.
5
Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production.严重急性呼吸综合征冠状病毒2刺突蛋白聚糖在病毒感染和抗体产生中的作用
Front Mol Biosci. 2021 Apr 13;8:629873. doi: 10.3389/fmolb.2021.629873. eCollection 2021.
6
How glycobiology can help us treat and beat the COVID-19 pandemic.糖生物学如何帮助我们治疗和战胜 COVID-19 大流行。
J Biol Chem. 2021 Jan-Jun;296:100375. doi: 10.1016/j.jbc.2021.100375. Epub 2021 Feb 4.
7
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.SARS-CoV-2 刺突糖蛋白的生物合成、结构、功能和抗原性：对基于刺突的疫苗免疫原设计的启示。
Front Immunol. 2020 Oct 7;11:576622. doi: 10.3389/fimmu.2020.576622. eCollection 2020.
8
SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.在非灵长类哺乳动物细胞中复制的 SARS-CoV-2 可能由于抗 Gal 抗体而对 COVID-19 疫苗具有关键优势：一篇迷你综述及建议。
J Med Virol. 2021 Jan;93(1):351-356. doi: 10.1002/jmv.26312. Epub 2020 Aug 2.
本文引用的文献
1
COVID-19 vaccine design: the Janus face of immune enhancement.COVID-19 疫苗设计：免疫增强的两面性。
Nat Rev Immunol. 2020 Jun;20(6):347-348. doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.
2
Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?抗体依赖增强作用在新冠病毒疾病发病机制中起作用吗？
Swiss Med Wkly. 2020 Apr 16;150:w20249. doi: 10.4414/smw.2020.20249. eCollection 2020 Apr 6.
3
The proximal origin of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的近端起源。
Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9.
4
SARS-CoV-2 Vaccines: Status Report.SARS-CoV-2 疫苗：现状报告。
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.
5
The SARS-CoV-2 Vaccine Pipeline: an Overview.严重急性呼吸综合征冠状病毒2型疫苗研发进展概述
Curr Trop Med Rep. 2020;7(2):61-64. doi: 10.1007/s40475-020-00201-6. Epub 2020 Mar 3.
6
Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).2019新型冠状病毒（2019-nCoV）与严重急性呼吸综合征冠状病毒（SARS-CoV）之间的结构、糖基化及抗原变异
Virusdisease. 2020 Mar;31(1):13-21. doi: 10.1007/s13337-020-00571-5. Epub 2020 Mar 5.
7
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸系统综合征冠状病毒 2 刺突糖蛋白的结构、功能和抗原性。
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
8
Timely development of vaccines against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗的及时研发。
Emerg Microbes Infect. 2020 Mar 8;9(1):542-544. doi: 10.1080/22221751.2020.1737580. eCollection 2020.
9
Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2.新型冠状病毒SARS-CoV-2高变基因组热点的鉴定。
J Infect. 2020 Jun;80(6):671-693. doi: 10.1016/j.jinf.2020.02.027. Epub 2020 Mar 5.
10
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV.与严重急性呼吸综合征冠状病毒（SARS-CoV）相比，新型抗体表位在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突糖蛋白的抗原性中占主导地位。
Cell Mol Immunol. 2020 May;17(5):536-538. doi: 10.1038/s41423-020-0385-z. Epub 2020 Mar 4.
Zotero 插件